Annexon(ANNX) - 2023 Q4 - Annual Results

Exhibit 99.1 Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024, a Global ShamControlled Trial Using Vision Preservation as Primary Outcome Measure Clinical Proof-of-Concept Data with ANX1502 Oral Inhibitor of the Classical Pathway Expected in Second Half of 2024 Rob ...